{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-028564","form_type":"8-K/A","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-07-15T21:09:08+00:00","discovered_at":"2026-07-15T21:10:00.283763+00:00","generated_at":"2026-07-15T21:10:05.303428+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gyre Therapeutics files Cullgen financials for merger; Cullgen FY2025 net loss $10.8M","bullets":["Cullgen FY2025 net loss $10.8M, accumulated deficit $132.2M as of Dec 31, 2025.","Cullgen revenue $15.4M from collaboration; R&D expense $19.3M, G&A $10.2M.","Cullgen had $40.2M in cash and short-term investments; total assets $53.6M.","Redeemable convertible preferred stock $173.5M; stockholders' deficit $127.4M.","Merger closed May 4, 2026; this amendment provides required financial statements."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-028564","json":"https://secwatch.observer/filing/0001140361-26-028564.json","markdown":"https://secwatch.observer/filing/0001140361-26-028564.md","text":"https://secwatch.observer/filing/0001140361-26-028564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126028564/0001140361-26-028564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126028564/ef20077460_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-15T21:10:05.303428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}